Abstract

Chikungunya virus (CHIKV) infections can cause severe and debilitating joint and muscular pain that can be long lasting. Current CHIKV vaccines under development rely on the generation of neutralizing antibodies for protection; however, the role of T cells in controlling CHIKV infection and disease is still unclear. Using an overlapping peptide library, we identified the CHIKV-specific T cell receptor epitopes recognized in C57BL/6 infected mice at 7 and 14 days post-infection. A fusion protein containing peptides 451, 416, a small region of nsP4, peptide 47, and an HA tag (CHKVf5) was expressed using adenovirus and cytomegalovirus-vectored vaccines. Mice vaccinated with CHKVf5 elicited robust T cell responses to higher levels than normally observed following CHIKV infection, but the vaccine vectors did not elicit neutralizing antibodies. CHKVf5-vaccinated mice had significantly reduced infectious viral load when challenged by intramuscular CHIKV injection. Depletion of both CD4+ and CD8+ T cells in vaccinated mice rendered them fully susceptible to intramuscular CHIKV challenge. Depletion of CD8+ T cells alone reduced vaccine efficacy, albeit to a lesser extent, but depletion of only CD4+ T cells did not reverse the protective phenotype. These data demonstrated a protective role for CD8+ T cells in CHIKV infection. However, CHKVf5-vaccinated mice that were challenged by footpad inoculation demonstrated equal viral loads and increased footpad swelling at 3 dpi, which we attributed to the presence of CD4 T cell receptor epitopes present in the vaccine. Indeed, vaccination of mice with vectors expressing only CHIKV-specific CD8+ T cell epitopes followed by CHIKV challenge in the footpad prevented footpad swelling and reduced proinflammatory cytokine and chemokines associated with disease, indicating that CHIKV-specific CD8+ T cells prevent CHIKV disease. These results also indicate that a T cell-biased prophylactic vaccination approach is effective against CHIKV challenge and reduces CHIKV-induced disease in mice.

Highlights

  • Chikungunya virus (CHIKV) is a mosquito-transmitted virus that causes fever, rash, and debilitating joint and muscle pain in humans

  • Few dominant CHIKV T cell epitopes have been experimentally described in C57BL/6 mice [23, 36]

  • To identify T cell epitopes recognized during CHIKV infection of C57BL/6 mice, we screened T cell responses by IFNγ enzyme-linked immune adsorben spot (ELISpot) using a CHIKV 18mer peptide library with 10 amino acid overlap

Read more

Summary

Introduction

Chikungunya virus (CHIKV) is a mosquito-transmitted virus that causes fever, rash, and debilitating joint and muscle pain in humans. Though the fever and rash resolve, joint and muscle pain can be long lasting. Up to 75% of CHIKV-infected patients experience chronic arthritic and muscle pain for months to years following resolution of the acute disease [1,2,3]. Potent neutralizing antibodies can provide sterilizing immunity if administered prophylactically or if derived through vaccination. After the first few days of infection, neutralizing antibodies may have limited efficacy to clear virus from infected tissues [9], suggesting other immune components, such as T cells, could be involved in viral clearance of persistent joint-localized CHIKV

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call